Treatment

PL1: placebo for Vericiguat, MK-1242, 2.5 mg and 5 mg clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic exploratory (Phase II)
A parallel-group treatment, phase 2a, double-blind, placebo-controlled 2-arm study to show improvement of physical function in SF-36 (SF-36-PF) in participants treated with Vericiguat compared to placebo tablets participants with post-COVID-19 syndrome without (PCS) or with (PCS/CFS) fulfillment of ME/CFS criteria - VERI-LONG
This study looks at a new medicine called Vericiguat for people with ongoing symptoms after COVID-19. It aims to see if Vericiguat can improve physical activity and reduce fatigue compared to a dummy pill.
For: Post-COVID-19 syndrome without (PCS) or with (PCS/CFS) fulfillment of myalgic encephalomyelitis/chronic fatique syndrome (ME/CFS) criteria
Germany